| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Marc Rubin is Director at CRIS, with reported holdings spanning 2 companies. Marc Rubin's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $89K at current prices.
Marc Rubin's largest disclosed position is in GALT as Director, worth about $69K. The GALT filings lean toward selling, a net 4,900 shares.
Marc Rubin has 28 Form 4 filings on record from January 2015 to July 2026, across 2 companies: Director at Curis (CRIS), 2015–2026; Director at Galectin Therapeutics (GALT), 2015–2025.
The 37 reported transactions were 25 option or other derivative awards, 4 stock awards, 2 open-market sales and 2 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $37K and 2 sales worth about $98K.
The largest open-market purchase was 25,000 shares of CRIS at an average $0.98 on November 16, 2017, about $25K.
The largest open-market sale was 11,900 shares of GALT at an average $6.58 on September 4, 2018, about $78K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 23, 2019 | CRIS Curis Inc | Director | Sell | 18,500 | $1.05 | $19,476.80 | -39.1% | |
| Sep 4, 2018 | GALT Galectin Therapeutics Inc | Director | Sale+OE | 11,900 | $6.58 | $78,255.59 | -36.6% | |
| Dec 8, 2017 | GALT Galectin Therapeutics Inc | Director | Buy | 7,000 | $1.85 | $12,971.70 | +14.4% | |
| Nov 16, 2017 | CRIS Curis Inc | Director | Buy | 25,000 | $0.98 | $24,500.00 | +94.0% |